查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1692291

抗體藥物偶聯物市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型、應用、地區和競爭細分，2020-2030 年

Antibody Drug Conjugates Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Types, By Application, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 187 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球抗體藥物偶聯物市場價值為 77.5 億美元，預計在預測期內將實現令人印象深刻的成長，到 2030 年的複合年成長率為 6.25%。抗體藥物偶聯物 (ADC) 市場是製藥和生物技術產業內一個充滿活力且快速發展的領域。 ADC 代表一類突破性的標靶癌症治療方法，它結合了單株抗體 (mAb) 的特異性與細胞毒性藥物的效力。這種協同作用能夠將強效的抗癌劑直接精確地輸送到癌細胞，同時保護健康組織，從而最大限度地減少與傳統化療相關的副作用。在多種關鍵因素的推動下，ADC 市場實現了大幅成長。首先，全球範圍內以及各種癌症類型的癌症發生率不斷上升，凸顯了對創新有效治療的迫切需求。 ADC 已成為一種有前景的解決方案，為治療選擇有限的患者提供更好的治療效果。

市場概況
預測期 2026-2030
2024 年市場規模 77.5 億美元
2030 年市場規模 110.6 億美元
2025-2030 年複合年成長率 6.25％
成長最快的領域 單株抗體
最大的市場 北美洲

主要市場促進因素

癌症發生率不斷上升

主要市場挑戰

腫瘤類型有限

主要市場趨勢

針對各種癌症適應症的 ADC 候選藥物不斷增加。

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第5章：全球抗體藥物偶聯物市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按類型（單株抗體、連接子、藥物/毒素、其他）
    • 依應用（血癌、乳癌、卵巢癌、肺癌、腦瘤、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第 6 章：北美抗體藥物偶聯物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 加拿大
    • 墨西哥

第 7 章：歐洲抗體藥物偶聯物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區抗體藥物偶聯物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲抗體藥物偶聯物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲抗體藥物偶聯物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 合併與收購

第 13 章：全球抗體藥物偶聯物市場：SWOT 分析

第 14 章：競爭格局

  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Seattle Genetics Inc
  • Genentech Inc
  • Immunogen Inc
  • Immunomedics Inc
  • Progenics Pharmaceuticals Inc
  • Bayer HealthCare Pharmaceuticals Inc

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 18756

Global Antibody Drug Conjugates Market was valued at USD 7.75 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.25% through 2030. The Antibody Drug Conjugates (ADCs) Market is a dynamic and rapidly evolving segment within the pharmaceutical and biotechnology industries. ADCs represent a groundbreaking class of targeted cancer therapies that combine the specificity of monoclonal antibodies (mAbs) with the potency of cytotoxic drugs. This synergy enables precise delivery of potent anticancer agents directly to cancer cells while sparing healthy tissue, thereby minimizing side effects associated with traditional chemotherapy. The market for ADCs has witnessed substantial growth driven by several key factors. Firstly, the increasing prevalence of cancer, both globally and across various cancer types, underscores the critical need for innovative and effective treatments. ADCs have emerged as a promising solution, offering improved therapeutic outcomes for patients with limited treatment options.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 7.75 Billion
Market Size 2030USD 11.06 Billion
CAGR 2025-20306.25%
Fastest Growing SegmentMonoclonal Antibodies
Largest MarketNorth America

Key Market Drivers

Growing prevalence of cancer

The growing prevalence of cancer serves as a compelling driver for the Global Antibody Drug Conjugates (ADCs) Market. Cancer has reached alarming proportions worldwide, with millions of new cases diagnosed annually. ADCs, a class of targeted cancer therapies, offer a ray of hope in the battle against this devastating disease. The rise in cancer cases underscores the unmet medical need for more effective and less toxic treatments. ADCs precisely deliver potent anticancer drugs to tumor cells, minimizing damage to healthy tissue, and hence are increasingly sought after. For instance, according to WHO, in 2022, an estimated 20 million new cancer cases and 9.7 million cancer-related deaths were reported globally. By 2050, the cancer burden is expected to rise by 77%, placing greater pressure on health systems and communities. In the WHO Eastern Mediterranean Region, over 788,000 cancer cases were diagnosed in 2022. This number is projected to double to 1.57 million by 2045 due to population growth and widespread risk factors, including tobacco use, obesity, physical inactivity, unhealthy diets, and air pollution. Addressing these risks is crucial to mitigating the rising cancer burden in the region.

Key Market Challenges

Limited Tumor Types

Limited tumor types targeted by Antibody Drug Conjugates (ADCs) pose a significant challenge in the global market. ADCs are highly specific, and their effectiveness depends on the presence of specific antigens on cancer cells. This restricts their applicability to a select range of tumor types, leaving many cancers without effective ADC treatment options. Developing ADCs for a broader spectrum of tumors requires identifying suitable target antigens and investing in extensive research and development. Additionally, regulatory approval for new ADCs can be time-consuming and costly. Overcoming the limitation of tumor types is crucial to expand the market's reach and impact in the oncology field.

Key Market Trends

Growing pipeline of ADC candidates for various cancer indications.

The growing pipeline of Antibody Drug Conjugate (ADC) candidates for various cancer indications is a noteworthy trend in the global ADC market. This trend reflects the increasing interest and investment in ADC research and development, driven by several factors: The ADC field has witnessed a surge in research and investment, leading to the development of a diverse range of ADC candidates. These candidates target various cancer indications, including solid tumors and hematological malignancies. This expansion of the therapeutic landscape is a response to the unmet medical needs across different cancer types. ADCs are known for their precision in targeting cancer cells while sparing healthy tissues. Advancements in genomics and biomarker discovery have enabled the identification of specific antigens and genetic profiles associated with different cancer types. This knowledge allows for the design of ADCs tailored to individual cancer subtypes, promoting personalized treatment approaches. The development of ADCs often goes hand in hand with research into combination therapies. Combining ADCs with other targeted therapies, immunotherapies, or standard chemotherapy regimens can enhance treatment efficacy. This trend aligns with the growing interest in combination approaches to address complex cancer biology. As cancer cells can develop resistance to single-agent therapies, researchers are exploring ADCs as a strategy to overcome resistance mechanisms. This has led to the development of ADCs that target specific resistance pathways or employ alternative mechanisms of action.

Key Market Players

  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Seattle Genetics Inc
  • Genentech Inc
  • Immunogen Inc
  • Immunomedics Inc
  • Progenics Pharmaceuticals Inc
  • Bayer HealthCare Pharmaceuticals Inc

Report Scope:

In this report, the Global Antibody Drug Conjugates Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antibody Drug Conjugates Market, By Type:

  • Monoclonal Antibodies
  • Linker
  • Drug/Toxin
  • Others

Antibody Drug Conjugates Market, By Application:

  • Blood Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Brain Tumor
  • Others

Antibody Drug Conjugates Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Antibody Drug Conjugates Market.

Available Customizations:

Global Antibody Drug Conjugates market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antibody Drug Conjugates Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Types (Monoclonal Antibodies, Linker, Drug/Toxin, Others)
    • 5.2.2. By Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Antibody Drug Conjugates Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Types
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Antibody Drug Conjugates Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Types
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Antibody Drug Conjugates Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Types
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Antibody Drug Conjugates Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Types
        • 6.3.3.2.2. By Application

7. Europe Antibody Drug Conjugates Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Types
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Antibody Drug Conjugates Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Types
        • 7.3.1.2.2. By Application
    • 7.3.2. United Kingdom Antibody Drug Conjugates Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Types
        • 7.3.2.2.2. By Application
    • 7.3.3. Italy Antibody Drug Conjugates Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Types
        • 7.3.3.2.2. By Application
    • 7.3.4. France Antibody Drug Conjugates Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Types
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Antibody Drug Conjugates Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Types
        • 7.3.5.2.2. By Application

8. Asia-Pacific Antibody Drug Conjugates Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Types
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Antibody Drug Conjugates Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Types
        • 8.3.1.2.2. By Application
    • 8.3.2. India Antibody Drug Conjugates Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Types
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Antibody Drug Conjugates Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Types
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Antibody Drug Conjugates Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Types
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Antibody Drug Conjugates Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Types
        • 8.3.5.2.2. By Application

9. South America Antibody Drug Conjugates Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Types
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Antibody Drug Conjugates Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Types
        • 9.3.1.2.2. By Application
    • 9.3.2. Argentina Antibody Drug Conjugates Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Types
        • 9.3.2.2.2. By Application
    • 9.3.3. Colombia Antibody Drug Conjugates Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Types
        • 9.3.3.2.2. By Application

10. Middle East and Africa Antibody Drug Conjugates Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Types
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Antibody Drug Conjugates Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Types
        • 10.3.1.2.2. By Application
    • 10.3.2. Saudi Arabia Antibody Drug Conjugates Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Types
        • 10.3.2.2.2. By Application
    • 10.3.3. UAE Antibody Drug Conjugates Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Types
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisition

13. Global Antibody Drug Conjugates Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Novartis AG
    • 14.1.1. Business Overview
    • 14.1.2. Treatment Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Key Personnel
    • 14.1.5. SWOT Analysis
  • 14.2. F. Hoffmann-La Roche Ltd
  • 14.3. Takeda Pharmaceutical Company Limited
  • 14.4. Pfizer Inc.
  • 14.5. Seattle Genetics Inc
  • 14.6. Genentech Inc
  • 14.7. Immunogen Inc
  • 14.8. Immunomedics Inc
  • 14.9. Progenics Pharmaceuticals Inc
  • 14.10.Bayer HealthCare Pharmaceuticals Inc

15. Strategic Recommendations

16. About Us & Disclaimer